Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $205 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Jazz Pharmaceuticals, maintaining a price target of $205.
September 10, 2024 | 9:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Jazz Pharmaceuticals, maintaining a price target of $205. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $205 price target by Needham suggests positive sentiment and confidence in Jazz Pharmaceuticals' future performance. This could lead to a short-term positive impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100